Inactivated- or killed-virus HIV/AIDS vaccines

Area of Science:

• Virology
• Vaccinology
• Immunology

Background:

• Classical inactivated or "killed" virus (KV) vaccines have a history of safety and efficacy in human and veterinary medicine.
• The development of an HIV/AIDS vaccine has largely overlooked the KV approach, favoring subunit (rgp120) and genetically engineered vaccines.
• Previous limitations for KV vaccines included concerns about cellular antigen responses and perceived loss of viral envelope during preparation.

Purpose of the Study:

• To discuss the rationale, pros, and cons of developing and testing killed-HIV vaccines.
• To evaluate the prospects for success of the KV approach in HIV/AIDS vaccine development.
• To outline the necessary research scope and review existing knowledge on killed-HIV vaccine candidates.

Main Methods:

• Review of historical scientific, technical, and sociological factors influencing vaccine approach selection.
• Analysis of recent findings regarding native trimeric gp120 epitopes and limitations of alternative vaccine strategies.
• Examination of pre-clinical development data for SIV and HIV KV candidates over the past 15 years.

Main Results:

• Subunit rgp120 vaccines have not demonstrated efficacy.
• Genetically engineered and vectored vaccines face challenges in eliciting strong cellular immune responses.
• Promising, though limited, pre-clinical data has emerged for several killed-SIV and killed-HIV vaccine candidates.

Conclusions:

• Renewed interest in the KV concept for HIV/AIDS vaccines is driven by the failures of other approaches and new insights into viral antigens.
• Further research is essential to fully explore the potential and overcome historical limitations of killed-virus vaccine strategies for HIV/AIDS.
• The classical killed-virus approach warrants continued investigation as a viable option for developing an effective HIV/AIDS vaccine.